349636-95-9Relevant academic research and scientific papers
Arylpropanolamines: Selective β3 agonists arising from strategies to mitigate phase I metabolic transformations
Washburn,Harper,Wu,Godfrey,McCann,Girotra,Shao,Zhang,Gavai,Mikkilineni,Dejneka,Ahmed,Caringal,Hangeland,Zhang,Cheng,Russell,Skwish,Slusarchyk,Allen,Frohlich,Abboa-Offei,Cap,Waldron,George,Tesfamariam,Dickinson,Seymour,Sher
, p. 4290 - 4296 (2008/02/12)
Utilization of N-substituted-4-hydroxy-3-methylsulfonanilidoethanolamines 1 as selective β3 agonists is complicated by their propensity to undergo metabolic oxidative N-dealkylation, generating 0.01-2% of a very potent α1 adrenergic
2,4-Thiazolidinediones as potent and selective human β3 agonists
Hu, Baihua,Ellingboe, John,Gunawan, Iwan,Han, Stella,Largis, Elwood,Li, Zenan,Malamas, Michael,Mulvey, Ruth,Oliphant, Alexander,Sum, Fuk-Wah,Tillett, Jeff,Wong, Victoria
, p. 757 - 760 (2007/10/03)
Methylsulfonamide substituted 2,4-thiazolidinedione 22c is a potent (EC50 = 0.01 μM, IA = 1.19) and selective (more than 110-fold over β1 and β2 agonist activity) β3 agonist. This compound has also been proven to be active and selective in an in vivo mode.
